Morning Immunotherapy Doubles Advanced Lung Cancer Survival Rates, Macron Maintains Cancer Fight Budget

A groundbreaking clinical study published on February 2, 2026, in Nature Medicine reveals that administering immunotherapy for advanced lung cancer in the morning nearly doubles patient survival rates. Led by Professor Francis Lévi, a CNRS oncologist, the research highlights how the timing of treatment leverages circadian rhythms to enhance immune response without altering drug composition or dosage. Patients treated in the morning showed significant improvement in tumor control and overall survival, marking a surprising and promising advancement in cancer therapy.

Coinciding with these scientific developments, French President Emmanuel Macron announced the continuation of a comprehensive cancer plan with over €1.7 billion allocated through 2030. This "decadal strategy" supports prevention, improved patient care, and accelerated screenings for cancers including breast, cervical, colorectal, and notably lung cancer. New initiatives under the plan include launching an organized lung cancer screening targeting 20,000 individuals aged 50 to 74 who are current or former smokers, aiming to reduce lung cancer mortality by 20-25%. The strategy prioritizes five key population groups: youth, elderly, workplace individuals, disabled persons, and residents of overseas territories.

Despite advances, misinformation remains a critical challenge. Medical oncologist Dr. Mario Di Palma warns of harmful effects caused by false cancer treatment beliefs, such as strict diets or unverified supplements, which can weaken patients and delay effective care. Patients' vulnerability to alternative therapies exploited by fraudulent actors poses serious health risks.

Professor Lévi expressed enthusiasm about the immunotherapy findings, stating the remarkable benefit of timing treatment to the body's biological rhythms. Meanwhile, Macron's sustained funding signals ongoing commitment to combating cancer, the leading cause of death among men and a top cause in women in France. Early detection efforts and reinforced research efforts under this strategy aim to build on medical advances like those in immunotherapy to improve patient outcomes in the coming years.